Dopamine surge is part of the reward circuity and common to all addiction

Dopamine (DA)

X        X

Development History

Stimuli --> DA Surge --> Craving

ALDH2 Inhibition: Published Pre-Clinical Efficacy Data

ANS-6637 Prevents dopamine surge which is common to all addiction

 

ANS-6637 is highly selective ALDH2 Inhibitor that prevents pathophysiologic dopamine surge and associated craving without changes to basal dopamine. This profile, which prevents craving and drug seeking behavior, has the potential to be used as pharmacotherapy for any substance and behavior based addiction.

In multiple pre-clinical models of substance abuse and anxiety, ALDH2 inhibition prevents dopamine surge without changes to basal dopamine levels, and

  • Prevents substance relapse
  • Reduces binge eating
  • Reduces anxiety

Stimuli --> DA Surge --> Craving

No Surge

No Craving

No Relapse

ANS-6637 prevents pathophysiologic DA surge without changes to basal DA

  • ALDH2 receptor research started at Harvard
  • CVT synthesized initial compounds (2009 Gilead acquires CVT)
  • Gilead invented GS-6637 (ANS-6637), a highly selective and reversible ALDH2-inhibitor
  • Composition of matter IP thru 2032+
  • Comprehensive manufacturing process and pre-clinical development
  • Preclinical efficacy in gold standard models of addiction relapse, anxiety and binge eating
  • Over 130 human subjects exposed to ANS-6637 in Phase-1 studies
  • Ready for outpatient Phase-2 studies 

​​Surges Trigger

Craving and

Relapse

​​Addiction hijacks the reward circuit to create pathophysiologic surges​​

Published Neurobiologic Model of Addiction and ANS-6637 Mechanism of Action